Showing results (31-40 of 112) with videos related to

Sort By:
Pageof 12
Cancer Treatment Reviews|July 28, 2017
Fertility and pregnancy issues in BRCA-mutated breast cancer patientsMatteo Lambertini, Oranite Goldrat, Angela Toss, et al.
Minerva Medica|April 28, 2020
The generally low sensitivity of CA 125 for FIGO stage I ovarian cancer diagnosis increases for endometrioid histotypeGiovanni Grandi, Anna M Perrone, Angela Toss, et al.
Minerva Obstetrics and Gynecology|May 14, 2021
Carboplatin-paclitaxel in triple-negative metastatic breast cancer during pregnancy with neoplastic thrombosisFrancesca Monari, Giovanni Grandi, Isotta Guidotti, et al.
Frontiers in Oncology|December 6, 2021
Obesity in Postmenopausal Breast Cancer Patients: It Is Time to Improve Actions for a Healthier Lifestyle. The Results of a Comparison Between Two Italian Regions With Different "Presumed" LifestylesLaura Cortesi, Giulia Raffaella Galli, Federica Domati, et al.
BMC Cancer|May 15, 2020
Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: to prescribe for the patient or the physician? A meta-analysis of phase II and III randomized clinical trialsClaudia Omarini, Federico Piacentini, Isabella Sperduti, et al.
Tumori|November 29, 2021
Italian pediatric and adult oncology communities join forces for a national project dedicated to adolescents and young adults with cancerAndrea Ferrari, Paola Quarello, Maurizio Mascarin, et al.
Magnetic Resonance Imaging|July 24, 2024
DCE-MRI Radiomic analysis in triple negative ductal invasive breast cancer. Comparison between BRCA and not BRCA mutated patients: Preliminary resultsAnnarita Pecchi, Chiara Bozzola, Cecilia Beretta, et al.
Oncology|August 30, 2017
Evaluation of Transvaginal Ultrasound plus CA-125 Measurement and Prophylactic Salpingo-Oophorectomy in Women at Different Risk Levels of Ovarian Cancer: The Modena Study Group Cohort StudyLaura Cortesi, Elisabetta De Matteis, Angela Toss, et al.
International Journal of Cancer|August 24, 2012
Tumor size, node status, grading, HER2 and estrogen receptor status still retain a strong value in patients with operable breast cancer diagnosed in recent yearsLaura Cortesi, Luigi Marcheselli, Valentina Guarneri, et al.
Cancer Treatment Reviews|March 31, 2024
Molecular characterization as new driver in prognostic signatures and therapeutic strategies for endometrial cancerElisa D'Agostino, Luciana Mastrodomenico, Ornella Ponzoni, et al.
Pageof 12